© 2026 Sinochem Nanjing Corporation,
All Right Reserved
Danofloxacin Mesylate traces its roots back to the fluorinated quinolone antibiotics developed in the late 20th century. Fluoroquinolones like danofloxacin showed promise against a wide range of bacteria at a time when livestock farming struggled with serious outbreaks and growing resistance to older drugs. Scientists needed something potent yet narrow enough to limit the risk of bacterial resistance crossing over into human medicine. As veterinary pharmaceutical research grew during the 1980s and 1990s, danofloxacin stood out as a solution for controlling respiratory and enteric diseases in cattle and poultry. It emerged from efforts to balance strong antibacterial results with practical dosing schedules and tolerable side effects for food-producing animals.
Danofloxacin Mesylate shows up as a veterinary drug, mainly used in injection or oral formulations. Its spectrum targets gram-negative and some gram-positive bacteria associated with major livestock health concerns, such as Mannheimia haemolytica and Pasteurella multocida, notorious for driving respiratory disease in cattle. Farmers and vets see it as a solid choice for treating outbreaks quickly, trimming down animal suffering and reducing economic losses in herds or flocks. Availability is usually through clear powders or ready-to-use injectable solutions, with specific instructions to safeguard food safety and limit misuse.
Danofloxacin Mesylate forms a slightly yellow crystalline powder with good water solubility, thanks to the mesylate salt. This property makes preparation and administration in livestock practical, as it dissolves cleanly in water for both oral and injectable needs. Chemically, it falls into the fluoroquinolone class, featuring a quinolone core structure attached to fluorine and piperazinyl groups, which underpin its antibacterial action. Slight bitterness marks its taste but rarely interferes with voluntary drinking in animals when given orally. Its stability at room temperature allows for transport and storage under typical farm conditions.
Labels on danofloxacin products carry strict details for species, recommended doses, withdrawal periods, and approved routes of administration. Standard labels will show concentration (for example, amount per milliliter for an injectable), batch number, expiration date, critical safety warnings, and storage directions. Veterinary authorities set limits on residue levels to protect consumers, so proper labeling links to traceability and enforcement. Labeling often draws attention to the need for veterinary oversight, reminding handlers of stewardship responsibilities and withdrawal timelines before animals go to slaughter or produce milk.
Commercial preparation involves synthesis from precursor quinolone structures, with the mesylate salt added in a controlled setting to improve solubility. This step-up process involves several chemical reactions—nitrating, reducing, cyclizing—until the molecule’s structure matches the blueprint for activity and safety. Manufacturers focus on achieving high purity, since micro-contaminants impact both effectiveness and regulatory acceptance. Final product undergoes rigorous filtration and drying before packaging, as pharmaceutical standards demand tight quality control. The powdered form gets weighed and sealed for further mixing before use, while injectable solutions must pass sterility tests.
Chemists working on danofloxacin mesylate sometimes experiment with modifications at the quinolone or piperazinyl positions, aiming for better absorption, lower toxicity, or higher potency. The presence of the mesylate salt proves valuable by boosting water solubility, which helps the drug act fast after administration. Common reactions in development include selective methylation and fluorination to tweak pharmacological traits, but once set, large-scale production stays consistent with the approved formula. In theory, researchers could swap different salts or add protective groups to adjust how the body handles the drug, though approved forms keep changes minimal for reliable outcomes.
In various regions, danofloxacin mesylate lands in the market under trade names such as Advocin, Aivlosin, or even generic titles that single out the mesylate salt. Literature sometimes calls it by its research code (CP-76,136). On technical sheets, it pops up as 1-Cyclopropyl-6-fluoro-1,4-dihydro-7-(1-piperazinyl)-4-oxo-3-quinolinecarboxylic acid methanesulfonate. Creating a clear link between these names helps buyers and inspectors stop confusion when comparing research, regulations, or shipment records. Recognizing synonyms matters when tracking side effects and trade flows across countries with different nomenclature customs.
Workers mixing, handling, or administering danofloxacin receive firm guidance: wear gloves, avoid inhaling dust, and prevent skin or mucous membrane contact. Veterinary medicine suppliers carry out regular safety drills to avoid accidental spills and contamination, recognizing that strong antibiotics require respect. On farms, personnel keep records of doses and withdrawal periods to avoid cross-contamination or unintentional medicated meat entering the food chain. Regulatory audits and safety data sheets call out routes of exposure and emergency steps, such as rinsing eyes or washing hands after contact. Local law often includes storage away from sunlight or heat and controlled disposal of expired or leftover stock.
The main use lands in commercial cattle, swine, and sometimes poultry production, targeting respiratory infections and some enteric illnesses that sideline animal growth and welfare. Danofloxacin mesylate’s action against gram-negative pathogens answers an ongoing demand to treat group outbreaks quickly, especially in densely stocked environments where traditional antibiotics struggle. In many countries, veterinarians seek it for treating shipping fever in cattle or acute outbreaks of salmonellosis, reducing reliance on broad-spectrum drugs that disturb beneficial flora. This approach fits a “treat-the-ill” philosophy, steering clear of blanket group prophylaxis to avoid resistance.
Academic labs and drug companies explore tweaks to the molecule, dosing strategies, and new delivery systems aimed at making danofloxacin mesylate more effective with less drug. Pharmacokinetic studies keep tracking how the drug moves in different animal species, seeking lower residues and shorter withdrawal periods. Researchers keep tabs on resistance profiles both in target bacteria and commensals, wary of genetic shifts that threaten the long-term usefulness of the drug. Surveillance programs track pathogens from treated farms for changes in sensitivity and try to link any resistance spikes to changes in veterinary prescription practices.
Animal trials often look at both acute and long-term effects, weighing the benefits for livestock against risks to consumers and the wider environment. Danofloxacin, like other fluoroquinolones, can disturb cartilage development in growing animals if used off-label, so age-restrictions and species restrictions exist in most regions. Toxicologists record rare side effects such as mild reactions at injection sites, stomach disturbances, or, in extreme cases, neurologic symptoms. On-farm observations matter—producers and vets report unexpected responses and residue testing at slaughter, helping authorities build a robust safety file. Labs also study any risk from chronic low-level exposure for farm workers or those living near treatment sites.
Efforts to fight antimicrobial resistance shape the future for drugs like danofloxacin mesylate. Regulators, researchers, and producers gravitate towards smarter, more targeted use in animals with strong justification for each prescription. Breakthroughs in diagnostics, such as rapid bacterial testing on farms, may guide choices toward danofloxacin only where it stands as the ideal therapy. There’s growing interest in further reducing environmental footprints, perhaps by designing drugs that degrade quickly after use or leave lower residues. Companies investing in alternative dosing routes or formulations stand to meet demands for animal welfare and food safety. The balance between keeping animals healthy, protecting public health, and supporting farmers keeps evolving, and danofloxacin mesylate remains under the spotlight as stakeholders press for clearer evidence and stricter oversight.
Danofloxacin Mesylate stands out as a fluoroquinolone antibiotic designed mainly for veterinary use. This substance goes into action by interrupting bacterial DNA replication, which stops harmful bacteria from growing. On farms, where livestock health is tightly connected to food security and the economy, farmers rely on solutions that keep herd infections in check. Cattle and pigs receive Danofloxacin injections or oral treatments to treat respiratory tract infections. These animals often face crowded, stressful barn life, making them easy targets for bacteria like Mannheimia haemolytica and Pasteurella multocida. These bugs can wreak havoc, causing pneumonia that reduces weight gain and, in serious cases, kills off whole groups of animals.
In my own experience growing up near a dairy farm, sick animals led to lost milk, more vet bills, and worried families. Seeing calves on antibiotics helped them bounce back quicker, saving both their lives and a chunk of family income. Danofloxacin acts fast and brings down the rate of deaths in herds facing outbreaks, which makes a big difference for small farms held together by thin margins.
On a bigger scale, making sure farm animals stay healthy means more stable supplies of beef, milk, and pork. Fewer animals get lost to disease, and farmers can sell their products without worrying about rejected shipments due to illness. Danofloxacin fits into this picture as one of the tools that keep food production running efficiently—and safely—while reducing the need for other, often harsher, antibiotics.
More people now wonder about what antibiotics like Danofloxacin mean for long-term food safety and public health. Overuse could make bacteria resistant, turning once-treatable infections stubborn and dangerous. According to the World Health Organization, resistance to fluoroquinolones already raises red flags in human medicine, with some infections no longer responding as expected. In the US, regulators limit Danofloxacin use to certain indications and require strict withdrawal periods, making sure drug residues don’t wind up in milk or meat. The veterinary community now spends more time double-checking dosages, animal weight, and test results, aiming to reduce unnecessary treatments.
This debate isn’t just science talk—it’s dinner table reality for families and food workers. The stakes feel personal for anyone trying to put food on shelves or fill lunchboxes with something healthy and safe. Smart antibiotic management doesn’t mean cutting off farmers from useful tools. It pushes everyone toward careful diagnosis, responsible prescribing, and regular training about disease prevention. Some farms now adopt more vaccination, cleaner barns, and tighter quarantine for sick animals, lessening the need for antibiotics like Danofloxacin.
The big challenge comes down to balance. Farmers need practical ways to stop the spread of bacteria without risking the drugs’ power for tomorrow. Tougher oversight, better data collection, and real farm education all help. Consumers, vets, and producers work together in this story, helped along by science and policy that keep up with changing risks. As someone who has seen both the relief that antibiotics bring and the concern they cause, I see sense in using Danofloxacin Mesylate only after other strategies make sick animals less likely in the first place. Supporting strong, healthy farms keeps the food system steady and meets growing calls for both safety and trust.
Farmers and veterinarians constantly look for ways to protect animal health and keep food supplies safe. Danofloxacin mesylate plays a significant role here. This antibiotic targets bacterial infections in some food-producing animals, especially cattle and swine. In my experience working alongside livestock handlers, few drugs match danofloxacin for tackling tough bugs when others fail.
Bovine respiratory disease sweeps through feedlots and ranches each season, causing stress to calves and losses for ranchers. Danofloxacin mesylate was developed with cattle in mind. It knocks out pathogens like Mannheimia haemolytica and Pasteurella multocida, which cause fever, cough, and rapid breathing. Field reports show good recovery rates when sick cows or feedlot steers receive the right injection. The speed and targeted approach of this treatment keep animals in the herd and reduce overall antibiotic use—vital as the world wrestles with antibiotic resistance.
Swine farmers face many of the same respiratory issues. Danofloxacin works against bacteria such as Actinobacillus pleuropneumoniae and Haemophilus parasuis, common in pig barns. I’ve seen entire pens turn around after using this medication properly under vet guidance. It doesn’t replace good biosecurity or ventilation, but for acute outbreaks, breeders rely on it to pull pigs through.
Some livestock owners get tempted to use powerful medications in sheep, goats, or poultry. Danofloxacin mesylate is not approved for these species. Risks outweigh potential benefits. Residues can end up in milk, eggs, or meat, which gets flagged by food safety authorities. Fines sting, but public trust drops even faster when misuse comes to light. I’ve listened to food inspectors urge everyone to stick to the rules—the right drug, in the right animal, for the right disease.
Antibiotics offer a lifeline, but overuse leads to resistance. Routine use isn’t the answer. Disease control begins with vaccines, clean water, and stress reduction. Vets help weigh costs and benefits before reaching for something as strong as danofloxacin. Monitoring withdrawal times means consumers get safe dairy and pork products.
Science keeps moving. New bacterial strains appear, and animal health companies invest in research to find new treatment options or improve odds of success with older drugs. The next solution could come from vaccines or management tweaks instead of another bottle or syringe.
Treating only cattle and swine with danofloxacin mesylate, for the diseases specified, protects more than the animals. This protects the health of people who count on safe food. Following label directions, working with veterinarians, and stepping up prevention sharpen the edge in the fight against animal illness. There is no shortcut. Healthy herds depend on thoughtful, evidence-based choices.
Choosing the right amount of Danofloxacin Mesylate can make or break treatment for infections in cattle and swine. This antibiotic comes up whenever tough respiratory bugs start causing trouble for herds. Picking a random amount doesn't work—anyone who has seen animals bounce back after a properly dosed course knows precision matters. Underdosing may leave infections lingering. Too much can cause residue issues and might even trigger resistance, which is fast becoming a real worry for farm operations worldwide.
The science behind Danofloxacin Mesylate offers some clarity for practical use. For cattle battling bovine respiratory disease—something anyone in the beef business has watched sweep through pens—the dose hovers around 1.25 mg per pound, or 2.5 mg per kilogram. Give this as a single injection under the skin, usually behind the shoulder. That sounds simple, but always weighing animals before treatment keeps things accurate. Guesswork risks both lost product and incomplete cures.
Pigs with respiratory troubles call for a different plan. The recommended dose goes with 6 mg per kilogram (2.73 mg per pound) injected into muscle, not under the skin. One shot usually does the job, but a few cases might need a second dose 48 hours later. That should always line up with a veterinarian’s advice, not just an internet search or label reading in the feed room.
Farmers walk a fine line between clearing up disease and keeping food safe for the next person in line. Residues left behind after antibiotics are a huge concern. The government checks this closely. With Danofloxacin, cattle need to wait at least four days after their last shot before heading to slaughter. Swine have a longer wait, at least six days. These “withdrawal times” aren’t mere suggestions—they help avoid trouble at the processing plant and keep consumers’ trust in their steaks and pork chops.
For anyone treating livestock, reading labels feels routine. But label directions only set the bare minimum. Vets often rely on a mix of textbook details and real-world experience. No two farms run exactly the same, and no two outbreaks hit with the same punch. Some herds might bounce back with a standard shot; others show complications that ask for a different plan. Testing bacteria with lab cultures takes time but can guide the right antibiotic choice. If Danofloxacin doesn't fit, reaching for something else early prevents wasted effort, frustration, and animal suffering.
Many hear the warnings about antimicrobial resistance but shrug them off as someone else’s problem. Reality says otherwise. Once resistance builds, drugs like Danofloxacin lose their punch, illness drags on, and treatment costs spike. Careful dosing—strictly following the prescription and not shaving doses to save money—makes a difference here. Extra attention to animal health, biosecurity, and vaccination plans slashes the number of outbreaks in the first place.
Veterinarians recommend checking scales every season. What looks like an average weight can change with breed, age, and feed program. Paper records or phone apps help track when doses get delivered and when the withdrawal clock starts. Only using Danofloxacin as directed and avoiding it for off-label use unless a vet specifically calls for it protects both animals and humans. Farm teams that learn, adjust, and check in with their local experts tend to stay ahead of both visible disease and hidden risk.
Ask any livestock farmer about keeping animals healthy, and you’ll hear plenty about the need to control infections. Respiratory and digestive problems pop up fast in crowded barns and feedlots. Danofloxacin mesylate is an antibiotic that’s been brought into the mix to fight some stubborn bugs in cattle, pigs, and poultry. This drug belongs to the fluoroquinolone family, a group with a reputation for dealing with tough infections.
Experience around farms and in veterinary clinics shows that every antibiotic brings its own pros and cons. Danofloxacin kills bacteria that regular medicines struggle with, which sounds good—until side effects show up. Asking about side effects isn’t just being cautious. It‘s about keeping herds healthy without trading one problem for another.
Animals treated with danofloxacin sometimes start off with mild stomach upset. Loose stools, changes in appetite, and an odd bout of vomiting aren’t rare. These changes usually don’t last, but farmers and vets watch for dehydration or slow growth if a whole group of calves gets dosed.
Swelling at the injection site crops up, especially if the animal moves too soon after getting a shot. I’ve seen lumps show up on a few calves, and they took a day or two to chill out and return to normal. Over time you learn to slow down, pick a better needle, and choose calmer cattle when possible.
What sets danofloxacin apart comes from the fluoroquinolone group’s long-term risks. In rare cases, animals have developed joint issues after treatment, especially growing calves and chickens. Scientists have traced this to the drug building up in weight-bearing cartilage. If a farmer counts on every animal staying sound for breeding or show, even a low risk seems worth thinking about.
Allergies aren’t common with danofloxacin, but they do show up. You may notice swelling, trouble breathing, or sudden rashes—signs that need a vet’s help right away. Most allergic reactions hit early and hard, so good records on previous medications matter.
One shadow hangs over all this: antibiotic resistance. Danofloxacin works against bacteria that ignore older treatments, but the bacteria can fight back. Long-term, careless use promises a future where even this tool stops working. That risk goes beyond barns. Residues could end up in food, or resistant strains might find their way into hospitals.
Dealing with side effects isn’t about throwing out good tools, but about management. Dosing animals with careful respect for size, age, and health history keeps most out of trouble. Rotating antibiotics, instead of leaning on danofloxacin as a catch-all, lets bacteria have fewer chances to adapt.
Farmers handle the daily side of this, but the bigger fight relies on everyone in food production chains. Routine testing, clear withdrawal times, and honest vet-farmer conversations make a difference. As with most things in agriculture, a little caution early saves big headaches later.
Danofloxacin Mesylate shows up often in vets’ cabinets, especially in large animal care. It’s a fluoroquinolone antibiotic, strong enough to tackle tough infections in cattle and pigs. Farmers and veterinarians trust it to treat respiratory illnesses that can sweep through herds quickly. Over the years, stories have traveled through farming communities—one neighbor watching a sick cow recover after treatment, another lamenting the rising tide of drug-resistant bugs. This medicine represents both hope and responsibility.
Farm supply stores sometimes feel like all-in-one stops, but walk in and ask for Danofloxacin Mesylate, and staff will want to see a prescription. U.S. federal law classifies this drug so veterinarians must call the shots. This rule comes straight from the Food and Drug Administration (FDA), which lists Danofloxacin as prescription-only due to potential health risks if used carelessly.
Why such strong oversight? Fluoroquinolones, including Danofloxacin, belong to a class of antibiotics that can shape bacteria in dangerous ways. If folks could buy these meds without proper vet supervision, livestock producers might overuse them or use them for the wrong illnesses. The World Health Organization and CDC have both warned that sloppy antibiotic use in food animals can build resistant bacteria, some of which pass into humans through food or close contact.
Everyone I’ve met in rural America has seen some illness run through a herd. The urge to get medicine fast turns real. On long nights watching over a sick animal, speed matters. But the risk that comes with self-medicating or skipping a vet’s guidance can defeat the whole purpose. Overdosing Danofloxacin, or using it when not needed, can lead to sick animals, meat residue violations, and superbugs that outsmart antibiotics.
Many developed countries, from the U.S. to members of the EU, keep tight controls around these drugs. Prescriptions help trace where and when antibiotics get used, giving public health officials important data if outbreaks happen. In my own experience working with small dairy farms, most owners accepted the extra step, once they understood the stakes. They have skin in the game; a single outbreak can ruin years of hard work.
Pharmacies and online sellers should never offer Danofloxacin Mesylate without demanding a prescription. Farms looking for speedy access can strengthen relationships with local vets. Mobile veterinary services and telemedicine appointments have closed the distance gap for some rural areas, making it easier to get treatment plans and prescriptions without waiting days. Cooperatives also invest in educational sessions to help farmworkers recognize symptoms before they turn into full-blown outbreaks.
Government agencies could step up with more funding for rural veterinary care and enforce compliance checks for online retailers. Making sure every prescription goes through a veterinarian protects food safety for millions. On-the-ground stories show that knowledge, access, and trust in animal care professionals move the needle more than strict laws alone. Every prescription requirement for Danofloxacin Mesylate draws a line between careful animal treatment and community health risk. Turning that line into real-world protection starts in clinics, fields, and feedlots, one conversation at a time.
| Names | |
| Preferred IUPAC name | 1-Cyclopropyl-6-fluoro-7-(4-methylpiperazin-1-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid methanesulfonate |
| Other names |
Advocin Danovet Danocin |
| Pronunciation | /ˌdæn.oʊˈflɒk.sə.sɪn ˈmɛs.ɪ.leɪt/ |
| Identifiers | |
| CAS Number | 115324-13-9 |
| Beilstein Reference | 1612753 |
| ChEBI | CHEBI:5976 |
| ChEMBL | CHEMBL19036 |
| ChemSpider | 4917848 |
| DrugBank | DB09022 |
| ECHA InfoCard | ECHA InfoCard: 100.233.686 |
| EC Number | 64228-44-0 |
| Gmelin Reference | 8341667 |
| KEGG | D07705 |
| MeSH | D007243 |
| PubChem CID | 10047762 |
| RTECS number | GQ7Z91336P |
| UNII | 0T2CM55T2F |
| UN number | UN2811 |
| Properties | |
| Chemical formula | C19H20FN3O3·CH4O3S |
| Molar mass | 425.49 g/mol |
| Appearance | white or almost white crystalline powder |
| Odor | Odorless |
| Density | 1.32 g/cm3 |
| Solubility in water | Slightly soluble in water |
| log P | -0.47 |
| Acidity (pKa) | 8.74 |
| Basicity (pKb) | 9.28 |
| Refractive index (nD) | 1.625 |
| Dipole moment | 9.6 D |
| Thermochemistry | |
| Std molar entropy (S⦵298) | 387.5 J·mol⁻¹·K⁻¹ |
| Pharmacology | |
| ATC code | J01MA92 |
| Hazards | |
| Main hazards | Harmful if swallowed. Causes serious eye irritation. May cause respiratory irritation. |
| GHS labelling | GHS05, GHS07, Danger, Causes serious eye damage, May cause respiratory irritation, Avoid breathing dust/fume/gas/mist/vapours/spray, Wear protective gloves/protective clothing/eye protection/face protection |
| Pictograms | GHS05,GHS07 |
| Signal word | Warning |
| Hazard statements | Harmful if swallowed. Causes serious eye irritation. May cause respiratory irritation. |
| Precautionary statements | Keep out of reach of children. Wear protective gloves and clothing. Avoid breathing dust or spray. Wash thoroughly after handling. If swallowed, seek medical advice immediately. |
| NFPA 704 (fire diamond) | NFPA 704: 2-3-0 |
| Flash point | Flash point: **220.6 °C** |
| Lethal dose or concentration | LD50 (oral, rat): 2000 mg/kg |
| LD50 (median dose) | LD50 (median dose) of Danofloxacin Mesylate: "2250 mg/kg (oral, rat) |
| NIOSH | Not Listed |
| PEL (Permissible) | PEL (Permissible Exposure Limit) for Danofloxacin Mesylate: Not established |
| REL (Recommended) | 8 mg/kg IM once |
| IDLH (Immediate danger) | Not Listed |
| Related compounds | |
| Related compounds |
Danofloxacin Ciprofloxacin Enrofloxacin Norfloxacin Levofloxacin Ofloxacin |
